EWA
BCRX icon

Exencial Wealth Advisors’s BioCryst Pharmaceuticals BCRX Stock Holding History

Exencial Wealth Advisors’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-10,000
Closed -$63K – 156
2016
Q4 		$63K Buy
+10,000
New +$52K 0.03% 165

Other funds holding BCRX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Exencial Wealth Advisors's BCRX Position: Q1 2017 in Review

Exencial Wealth Advisors sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2017, closing a stake of 10,000 shares — an estimated $63K sold.

Exencial Wealth Advisors first reported a position in BCRX in Q4 2016 and held it in 1 quarter. The position peaked at $63K in Q4 2016. 117 funds tracked by Wall St. Rank hold BCRX as of Q1 2017.

  • Exencial Wealth Advisors reported no remaining BioCryst Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Exencial Wealth Advisors sold 10,000 BioCryst Pharmaceuticals shares in Q1 2017, an estimated $63K.
  • Exencial Wealth Advisors first reported a position in BioCryst Pharmaceuticals in Q4 2016 and held it in 1 quarter.
  • Exencial Wealth Advisors's BioCryst Pharmaceuticals position peaked at $63K in Q4 2016.
  • 117 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2017.

Based on Exencial Wealth Advisors's 13F filing for Q1 2017, filed 26 Apr 2017.